Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 4.9%

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) traded up 4.9% on Monday . The stock traded as high as $15.78 and last traded at $15.76. 10,774 shares changed hands during mid-day trading, a decline of 86% from the average session volume of 76,655 shares. The stock had previously closed at $15.02.

Gyre Therapeutics Stock Down 4.4 %

The stock has a fifty day moving average price of $12.19 and a 200-day moving average price of $15.00.

Gyre Therapeutics (NASDAQ:GYRE) last posted its quarterly earnings data on Thursday, May 9th. The company reported $0.04 earnings per share for the quarter. The firm had revenue of $27.17 million during the quarter. Sell-side analysts forecast that Gyre Therapeutics, Inc. will post -0.45 EPS for the current year.

Insider Transactions at Gyre Therapeutics

In related news, Director Nassim Usman sold 3,452 shares of the stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $12.00, for a total transaction of $41,424.00. Following the completion of the transaction, the director now directly owns 1,636 shares of the company’s stock, valued at $19,632. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.92% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Gyre Therapeutics stock. Bank of New York Mellon Corp bought a new position in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 18,266 shares of the company’s stock, valued at approximately $218,000. 23.99% of the stock is owned by institutional investors and hedge funds.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.